Funding (a Capricorn Consilium project)
Themis Bioscience is an international biotech company that successfully develops vaccines against emerging and specialist indications like Chikungunya, Zika or Dengue virus vaccines.
Following a successful start based on seed and series A funding, Themis kicked-off the series B funding activities. Capricorn Consilium has been approached for support.
Capricorn Consilium focused on contacts to Venture Capital firms. The joint activities led to a successful series B funding.
28 November 2016
Themis Bioscience Successfully Closes 10 M EUR Financing Round
Following please find recommended partners of Capricorn Consilium GmbH:
ZMM Zeitmanager München GmbH
GPN Vaccines Pty Ltd
Vacthera BioTech GmbH
Capricon Consilium overview as PDF:
Capricorn Consilium Presentation
General Manager . Consultant . Interim Management
Capricorn Consilium GmbH
An der Wehr 6
2440 Reisenberg . Austria
FN: FN 410215 h . HG Wiener Neustadt . ATU68487489
M: +43 (0) 676 930 33 70
T: +43 (0) 1 941 8868
F: +43 (0) 1 2533 033 7513